Table I.
Patients clinicopathological characteristics.
| Clinical factor | Number of patients (%) |
|---|---|
| Gender | |
| Male | 19 (76) |
| Female | 6 (24) |
| Age, years | |
| Median ± SD | 66.0±6.5 |
| <70 | 18 (72) |
| ≥70 | 7 (28) |
| Indications for chemotherapy | |
| Recurrence following surgery | 9 (36) |
| Advanced cancer | 16 (64) |
| Recurrent or metastatic sites | |
| Mediastinal lymph node | 8 (32) |
| Pleural dissemination | 6 (24) |
| Adrenal gland | 5 (20) |
| Brain | 4 (16) |
| Bone | 3 (12) |
| Liver | 2 (8) |
| Other | 2 (8) |
| Histology | |
| Squamous cell carcinoma | 11 (44) |
| Adenocarcinoma | 13 (52) |
| Large cell carcinoma | 1 (4) |
| EGFR mutation | |
| Positive | 5 (20) |
| Wild type | 16 (64) |
| Unknown | 4 (16) |
| ALK rearrangement | |
| Positive | 0 (0) |
| Negative | 6 (24) |
| Unknown | 19 (76) |
| Phase of nab-paclitaxel chemotherapy | |
| 2nd line | 13 (52) |
| 3rd line | 6 (24) |
| 4th line | 3 (12) |
| 5th line | 2 (8) |
| 6th line or later | 1 (4) |
SD, standard deviation; EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase; nab, nanoparticle albumin-bound.